| Prev Close | 182.79 |
| Open | 182.86 |
| Day Low/High | 182.17 / 186.60 |
| 52 Wk Low/High | 112.60 / 187.67 |
| Volume | 916.63K |
McKesson Corporation (MCK)
185.01
2.22
1.21
NYSE
| Exchange | NYSE |
| Shares Outstanding | 160.56B |
| Market Cap | 29.57B |
| P/E Ratio | 14.31 |
| Div & Yield | N.A. (N.A) |
Eclipse in the USA: Then and Now
A video of what's changed in the thirty plus years since the last eclipse
Finding Value in a Pricey Environment
As McKesson shows, not every good company is priced to perfection.
Cramer: You Need 2 Monday Morning Game Plans
We really want to shake out the weak hands here.
These Stocks Are Changing Direction
Finding bullish and bearish reversals in the market.
Cramer: The Rebound is Real. Now What?
With stocks rebounding, investors face a tough choice.
After the Bell Results
(Please be aware that all of the following quotes are rapidly changing as more information becomes available.) Salesforce.com is trading slightly higher after hours after reporting 28 cents (adjusted) vs. 26 cents (forecast). Salesforce is trading ...
McKesson: Bears Still Have the Upper Hand
MCK has rolled over again and prices are pointed lower
McKesson Offers Healthy Upside Potential
You need to see where the health services giant normally trades to appreciate how undervalued it is.
Buy Retail, Pharma, Health-Care on Dips
Demographics will continue to favor health-care and pharmaceutical companies.
My Takeaways and Observations (3:30 p.m. Edition)
The markets started the day like Usain Bolt at the start of a 100-meter race. But, unlike Bolt, the finish wasn't as strong as the start. I thought one of the day's features was the reversal in bond yields, particularly after the good data. The...
Mizuho Analysts Share Their Top Stock Picks for 2017
Apple, Energen and McKesson are among the top stock picks of Mizuho's analysts for 2017.
My Takeaways and Observations
"Everyone here likes the bounce." -- President-elect Donald Trump (said in a meeting today at Trump Tower with tech executives) A good day for the ursine crowd but not so good for the bullish cabal as they had a bad day -- for a change. (Yes, I am w...
3 Bargain-Priced Health-Care Stocks
Current valuations are at record lows, despite the companies having good prospects.
Uncertainties Making it Difficult for Investors in the Healthcare Sector, says Mizuho Analyst
Since the election, big questions remain about investing in hospital and healthcare stocks, and the group will remain volatile according to Mizuho.
Andrew Left: Dump Mallinckrodt
Famed short-seller says drugmaker at risk of a government crackdown.
My Takeaways and Observations
"Today I am asking myself ... Did the FANG names just peak the way iShares NASDAQ Biotechnology Index ETF IBB did in 2015 and Energy Select Sector SPDR ETFXLE did in 2014? The S&P 500 Index kept rising, but those two groups were done!" -- Kass Diar...
Cramer: Don't Just Stand There Like Bambi; Sell Some
Stocks in the health care sector seem to have no underpinnings whatsoever.
Cramer: Health Care Sector Is Hurting
You can't ignore the evidence.
My Takeaways and Observations (Early Edition)
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
ZBH's Big Unjustified Price Correction
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Valeant Skyrockets on Rumored $10B Salix Sale
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.
Cramer: How Bad Was Today? Let Us Count the Ways
Today there was a virtual vacuum of good news in the stock market.
Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
Morning Movers: PFE, K, VRX, AEP
Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.
Valeant's Frightful Halloween
Troubled drug firm sheds 12% on fresh fraud news.
Cramer: Nike Is a Victim of Price Wars; There Will Be Others
Look out below when it comes to margins, as the price wars extend to sneakers, drugs and others.
